JPS61103861A - Preparation of aryl-substituted cyanoacetic acid ester - Google Patents

Preparation of aryl-substituted cyanoacetic acid ester

Info

Publication number
JPS61103861A
JPS61103861A JP59226071A JP22607184A JPS61103861A JP S61103861 A JPS61103861 A JP S61103861A JP 59226071 A JP59226071 A JP 59226071A JP 22607184 A JP22607184 A JP 22607184A JP S61103861 A JPS61103861 A JP S61103861A
Authority
JP
Japan
Prior art keywords
group
formula
aryl
general formula
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP59226071A
Other languages
Japanese (ja)
Inventor
Shigetoshi Takahashi
成年 高橋
Mitsunari Uno
宇野 晃成
Koji Seto
浩二 瀬戸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Kasei Co Ltd
Original Assignee
Nitto Kasei Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Kasei Co Ltd filed Critical Nitto Kasei Co Ltd
Priority to JP59226071A priority Critical patent/JPS61103861A/en
Publication of JPS61103861A publication Critical patent/JPS61103861A/en
Pending legal-status Critical Current

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/52Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

PURPOSE:To obtain the titled compound useful as a synthetic intermediate of pharmaceuticals, agricultural chemicals, dyes, functional polymers, organic electrically conductive materials, etc., in high yield, by reacting an aryl halide with a cyanoacetic acid ester in the presence of a small amount of a specific catalyst. CONSTITUTION:The objective compound of formula II or III can be prepared by reacting the aryl halide of formula Ar-Xm or formula I (Ar if aryl or arylene; X is halogen; Y is O, S or alkylene; m is 1 or 2; n is 0 or 1) with the cyanic acid ester of formula CNCH2COOR<1> (R<1> is alkyl, aralkyl or aryl) in nitrogen gas stream in the presence of a catalayst and basic condensation agent, in a solvent at 20-140 deg.C. The reaction is carried out in the presence of a catalyst consisting of a bivalent palladium complex of formula QaPd(II)X*b (Q is nitrile, pi-allyl, 1,5-diene, etc.; X*b is halogen; a and b are 1 or 2) and ligand compound of formura IV (Z is P, As, Sb, etc.; R<3>-R<5> are alkyl, alkenyl, aryl, etc.).

Description

【発明の詳細な説明】 本発明はアリール置換シアン酢酸エステルの製造法に関
する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a process for producing aryl-substituted cyanacetic esters.

従来から塩基性縮合剤及び溶媒の存在下でアルキルハラ
イドとシアン酢酸エステルを反応させ容易にアルキル置
換シアン酢酸エステルを合成できることはよく知られて
いる。しかしながら、アルキルハライドの代シにアリー
ルハライドを用いり場合には、アリールハライドとシア
ン酢酸エステルとを全く反応させることができなかった
It has been well known that an alkyl-substituted cyanacetate can be easily synthesized by reacting an alkyl halide with a cyanacetate in the presence of a basic condensing agent and a solvent. However, when aryl halide was used instead of alkyl halide, it was not possible to cause the aryl halide and cyanacetic acid ester to react at all.

本発明者等は種々研究の結果、特定の触媒を用いて行な
えば、アリールハライドでもシアン酢酸エステルと反応
させることができ、高収率でアリール置換シアン酢酸エ
ステルを得ることに成功した。
As a result of various studies, the present inventors have succeeded in obtaining aryl-substituted cyanacetate in high yield by reacting even aryl halide with cyanacetate by using a specific catalyst.

すなわち1本発明は、触媒、塩基性縮合剤及び溶媒の存
在下に。
That is, in the present invention, in the presence of a catalyst, a basic condensing agent, and a solvent.

一般式 %式% (式中Arはアリール基又はアリーレン基を、Xはハロ
ゲン原子を、Yは一〇−、−S−又はアルキレン基を2
mは1又は2の整数を、nはO又は1の整数をそれぞれ
示す)で表わされるアリールハライドに 一般式 %式% (式中R1はアルキル基、アラルキル ル基を示す)で表わされるシアン#酸エフチルを反応さ
せるに当シ,触媒として (a)一般式 %式%) 〔式中Qはニトリル類,インニトリル類,π−アリル、
1.5−ジエン類.1.3−ジエン類,ベンゾキノン又
はオレフィン類を示し,但し,これらの化合物ばPd(
If)錯体を形成するものとし,X*はハロゲン原子を
,a及びbは1又は2の整数をそれぞれ示す〕で表わさ
れる二価のパラジウム錯体と (b)一般式 (式中zはリン原子,ヒ素原子又はアンチモン原子ヲ,
R3,托4又は凡5はアルキル基,アルケニル基。
General formula%Formula% (In the formula, Ar represents an aryl group or an arylene group, X represents a halogen atom, and Y represents a 10-, -S-, or alkylene group.
m is an integer of 1 or 2, and n is an integer of O or 1, respectively) to an aryl halide represented by the general formula % (in which R1 represents an alkyl group or an aralkyl group). For the reaction of ethyl, as a catalyst (a) general formula % formula %) [wherein Q is nitrile, innitrile, π-allyl,
1.5-Dienes. 1. Indicates 3-dienes, benzoquinone or olefins, provided that these compounds are Pd (
If) a divalent palladium complex represented by the general formula (wherein z is a phosphorus atom) and , arsenic atom or antimony atom,
R3, 4 or 5 is an alkyl group or an alkenyl group.

アラ/レキ/し基,アリ−/し基.シクロアルキルアル
コキシ基又はアリールオキシ基から独立して選ばれた基
を示し,R31ft’又はR5が他の分子のR3。
Ara/reki/shi group, ary/shi group. Represents a group independently selected from a cycloalkylalkoxy group or an aryloxy group, and R31ft' or R5 is R3 of another molecule.

R4又はR5 と互に結合し tになくとも1個のアル
キレン基又はアルキレンエーテル基を形成シていてもよ
い)で表わされる配位子化合物を用いて該反応を行なう
ことを特徴とする。
The reaction is characterized in that the reaction is carried out using a ligand compound represented by R4 or R5 (which may be bonded to R4 or R5 to form at least one alkylene group or alkylene ether group in t).

一般式 (式中Ar+R”+Y+m及びnは上記と同じ意義を有
する)で表わされるアリール置換シアン酢酸エヌテルの
製造法である。
This is a method for producing an aryl-substituted cyanoacetate ether represented by the general formula (wherein Ar+R"+Y+m and n have the same meanings as above).

本発明方法において用いる一般式 %式%() で表わされる二価のパラジウム錯体においてQとしては
,例えばベンゾニトリル、ベンゾイソニトリル、π−ア
リル、シクロヘキサジエン、シクロオクタンニン.ノル
ホルナシエン,ブタジェン。
In the divalent palladium complex represented by the general formula % (%) used in the method of the present invention, examples of Q include benzonitrile, benzisonitrile, π-allyl, cyclohexadiene, cyclooctanine. norformacien, butadiene.

テトラフェニルシクロゲタジエン、ペンゾキノンヌチレ
ン,πーシクロペンタジェニルfxトカ挙Iffられ,
これらの化合物はFd(If)化合物の存在によりそれ
ぞれニド リルrd(口)錯体,イソニトリルpa (
ff )錯体,πーアリルpd(U)8体.l 、5−
シエンPd(ロ)錯体、1.3−ジエンPa([1)錯
体、ベンゾキノンPd([1)錯体、オレフィンPd(
ロ)錯体を形成する。
Tetraphenylcyclogetadiene, penzoquinone tylene, π-cyclopentagenyl fx,
Due to the presence of the Fd(If) compound, these compounds are nidril rd (or) complex and isonitrile pa (
ff) complex, π-allyl pd(U) 8-body. l, 5-
Cyene Pd(b) complex, 1,3-diene Pa([1) complex, benzoquinone Pd([1) complex, olefin Pd(
b) Form a complex.

またX*とじては塩素原子、臭素原子、ヨウ素原子など
が挙けられる。
Examples of X* include chlorine atom, bromine atom, and iodine atom.

また上記二価のパラジウム錯体に添加して用いる一般式 %式% で表わされる配位子化合物としては1例えば(CEi;
)J’。
In addition, as a ligand compound represented by the general formula % formula % which is added to the above divalent palladium complex, 1, for example (CEi;
)J'.

CC2H3)3P 、  (CH2=CHCH2)3F
 、  (C3H7)3F 、  (C41=[9)3
1’  。
CC2H3)3P, (CH2=CHCH2)3F
, (C3H7)3F , (C41=[9)3
1'.

(C5H1□)3F 、 (C6H13)3F 、 (
C7H1,)3F 、 (08H17)3F 。
(C5H1□)3F , (C6H13)3F , (
C7H1,)3F, (08H17)3F.

(C6H1□)3F  、  (06H6)3F 、 
 (CH3C6H4)3F 、  (C4C,1i4)
3P  。
(C6H1□)3F, (06H6)3F,
(CH3C6H4)3F, (C4C,1i4)
3P.

(CH3006H4)3P 、 (C6H5CH2)3
F 、 (04H9)2(C6H5)P 。
(CH3006H4)3P, (C6H5CH2)3
F, (04H9)2(C6H5)P.

(C4H3)(06M5)2P 、 (OH3QC,H
4)(0,H5)2F 。
(C4H3) (06M5)2P , (OH3QC,H
4)(0,H5)2F.

(C6H5)2PCH2Ca20CH2C,H4F<C
,6H5)2. (OH30)3F 。
(C6H5)2PCH2Ca20CH2C, H4F<C
,6H5)2. (OH30) 3F.

(C2H50)3P 、(C3H70)3F 、(C4
鴇0)3F  、  (0,J:11□0)3F。
(C2H50)3P , (C3H70)3F , (C4
Toki0)3F, (0,J:11□0)3F.

(C8H,0)3P 、  (C6にCH20)3F 
、  (C6H,0)3P 。
(C8H,0)3P, (CH20 to C6)3F
, (C6H,0)3P.

(C1i3C6H40)3F  、(C6C6H40)
3P  、(CH30C6H40)3P  。
(C1i3C6H40)3F , (C6C6H40)
3P, (CH30C6H40)3P.

(OH30XC6H3)2P 、 (04H0O)2(
C6H5)P 、 (C1i3C6H40) (C,H
5) 2P 。
(OH30XC6H3)2P, (04H0O)2(
C6H5)P , (C1i3C6H40) (C,H
5) 2P.

(C4H90)(C6鴇0)2Pなどのリン化合物、(
CH3)3As  +(C2H6)3As I (CH
2=C)IcH2)3As l (03H7)3As 
1(C4H3)3As  T  (L;、R1ρ3As
  l  (C8H07)3AS  、  (06H,
0H2)3As。
Phosphorus compounds such as (C4H90)(C6鴇0)2P, (
CH3)3As + (C2H6)3As I (CH
2=C)IcH2)3As l (03H7)3As
1(C4H3)3As T (L;, R1ρ3As
l (C8H07)3AS, (06H,
0H2)3As.

(C,H5)3As 、 (OH3C,H4)3As 
、 (OH3QC6H,)3As 。
(C,H5)3As, (OH3C,H4)3As
, (OH3QC6H,)3As.

(C6C,H4)3As l (0,H,)2AsCH
20H2A5(06H,)2などのヒ素化合物、 (C
H3)3Sb 、 (C,H,)38b 、 (OH2
=CHCH2)3Sb。
(C6C,H4)3Asl (0,H,)2AsCH
Arsenic compounds such as 20H2A5(06H,)2, (C
H3)3Sb, (C,H,)38b, (OH2
=CHCH2)3Sb.

(03H,)3Sb 、 (04H3)3Sb 、 (
CsHta)3Sb 、 (C6H3)38b 。
(03H,)3Sb, (04H3)3Sb, (
CsHta)3Sb, (C6H3)38b.

CC106H4)38b 、 (CH3C6H4)3S
b 、 (CH3QC吃4)38b r(C6H,)2
SbCH2CM2Sb (0,H,;)2などのアンチ
モン化合物等が挙げられる。
CC106H4)38b, (CH3C6H4)3S
b , (CH3QC吃4)38b r(C6H,)2
Examples include antimony compounds such as SbCH2CM2Sb (0,H,;)2.

本発明方法においてシアン酢酸エステルと反応させるア
リールハライドとしては1例えば一般式 で表わされる化合物が挙げられる。
Examples of the aryl halide to be reacted with cyanacetate in the method of the present invention include compounds represented by the general formula.

上記式中Xは塩素原子、臭素原子、ヨウ素原子をR6は
水素原子、ハロゲン原子、ニトリル基。
In the above formula, X is a chlorine atom, a bromine atom, or an iodine atom, and R6 is a hydrogen atom, a halogen atom, or a nitrile group.

アセチル基、7ルコキシ基、アルキル基、アリール基、
アラルキル基、アリールオキシ基などの置換基から独立
して選ばれ+ R’は水素原子又は低級アルキル基を1
mは1〜2の整数を、pは1〜5の整数を19は1〜4
の整数をそれぞれ示す。
Acetyl group, 7-lukoxy group, alkyl group, aryl group,
independently selected from substituents such as aralkyl groups and aryloxy groups + R' represents a hydrogen atom or a lower alkyl group
m is an integer from 1 to 2, p is an integer from 1 to 5, and 19 is an integer from 1 to 4.
Indicate each integer.

ここでXはヨウ素原子が最も好ましい。またアリールハ
ライドにおいて+ R’にハロゲン置換基がある場合に
はシアン酢酸エステルに対する反応性は ヨウ素〉〉臭素〉塩素 の順に大きくなる。
Here, X is most preferably an iodine atom. Further, when there is a halogen substituent at +R' in the aryl halide, the reactivity toward cyanacetate increases in the order of iodine>>bromine>chlorine.

本発明方法において、アリールハライドと反応させるシ
アン酢酸エステルとしては1例えば。
In the method of the present invention, the cyanacetic acid ester to be reacted with the aryl halide includes, for example, 1.

シアン酢酸メチル、シアン酢酸エチル、シアン酢酸プロ
ピル、シアン酢酸ブチル、シアン酢酸アミル、シアン酢
酸オクチル、シアン酢酸ベンジル。
Methyl cyanogen acetate, ethyl cyanogen acetate, propyl cyanogen acetate, butyl cyanogen acetate, amyl cyanogen acetate, octyl cyanogen acetate, benzyl cyanogen acetate.

シアン酢酸フェニルなどが挙げられ、シアン酢酸メチル
、シアン酢酸エチル、シアン酢酸プロピルが最もよく利
用される。
Examples include phenyl cyanacetate, and methyl cyanacetate, ethyl cyanacetate, and propyl cyanacetate are most commonly used.

本発明方法は通常次のようにして行なわれる。The method of the present invention is generally carried out as follows.

すなわち、窒素気流中で反応容器に塩基性縮合剤と溶媒
を入れ、溶媒にとかしたシアン酢酸エステルを徐々に加
えて反応させ、その後アリールハライドど二価のパラジ
ウム錯体及び配位子化合物の触媒を添加し、一定時間反
応を行なった後。
That is, a basic condensing agent and a solvent are placed in a reaction vessel in a nitrogen stream, and cyanacetic acid ester dissolved in the solvent is gradually added to cause a reaction, and then a divalent palladium complex such as an aryl halide and a catalyst of a ligand compound are added. After adding and reacting for a certain period of time.

度広生成物を取り出す。生成物の分離・精製は再結晶法
、クロマト分離法、昇華法などを利用して行なわれる。
Take out the diluted product. Separation and purification of the product is performed using a recrystallization method, a chromatographic separation method, a sublimation method, etc.

塩基性縮合剤としては2例えばナトリウム。Examples of basic condensing agents include sodium.

カリウムなどのアルカリ金属、メトキシナトリウム、二
トキ・ジナトリウム、イソプロポキシナトリウム、t−
ブトキシカリウム、t−アミロキシナトリウムなどのア
ルカリ金属アルコラード、カリウ°ムアミド、リチウム
アミド、ナトリウムアミドなどのアルカリアミド、水素
化ナトリウム、トリフェニルメチルナトリウムなどが挙
げられる。
Alkali metals such as potassium, sodium methoxy, di-disodium, sodium isopropoxy, t-
Examples include alkali metal alcoholades such as butoxypotassium and t-amyloxysodium, alkali amides such as potassium amide, lithium amide, and sodium amide, sodium hydride, and triphenylmethyl sodium.

反応溶媒としては1例えばテトラヒドロフラン、エチレ
ングリコールジメチルエーテ/L/、シエチレンクリコ
ールジメチルエーテ/L/Iジエチルエーテル、ジプチ
ルエーテル、ジオギサン、Δキサメチlレホスホルトリ
アミド、ジメチルホルムアミド及びこれらと炭化水素と
の混合溶媒などが挙げられる。
Examples of reaction solvents include tetrahydrofuran, ethylene glycol dimethyl ether/L/I, ethylene glycol dimethyl ether/L/I diethyl ether, diptyl ether, dihysane, Δxamethylene phosphorotriamide, dimethylformamide, and combinations of these and hydrocarbons. Examples include a mixed solvent of .

反応温度は20〜150℃、好ましくは 50〜80℃
で行われ9反応時間は温度によって変るが。
Reaction temperature is 20-150℃, preferably 50-80℃
The reaction time varies depending on the temperature.

例えば70℃で5時間以上である。そして反応中は不活
性ガフ雰囲気下で行うことが望ましい。
For example, at 70°C for 5 hours or more. During the reaction, it is desirable to carry out the reaction under an inert gaff atmosphere.

本発明方法においては、二価のパラジウム錯体と配位子
化合物を触媒として添加して行なわれる。
In the method of the present invention, a divalent palladium complex and a ligand compound are added as catalysts.

二価のパラジウム錯体と配位子化合物との添加割合は、
任意でよいが、好ましくは12(モル比)であり、また
両者の添加量はアリールハライドとシアン酢酸エステル
の両原料1モルに対して1/10〜1/10000モノ
′を好ましくは1/100〜1/sooモルで あ る
 。
The addition ratio of the divalent palladium complex and the ligand compound is
It may be arbitrary, but preferably 12 (molar ratio), and the amount of both added is 1/10 to 1/10,000 mono', preferably 1/100 to 1 mole of both raw materials of aryl halide and cyanacetic ester. It is ~1/soo mole.

本発明における触媒の作用機構は定かではないが、二価
のパラジウム錯体におけるQが配位子化合物と置換して
生じた化合物が触媒として作用していると思われる。
Although the mechanism of action of the catalyst in the present invention is not clear, it is thought that the compound produced by replacing Q in the divalent palladium complex with a ligand compound acts as a catalyst.

本発明方法によれば、アリールハライドとシアン酢酸エ
ステルを極めて少量の触媒を使用して反応させ、高収率
でアリール置換シアン酢酸エステルを得ることができる
ので、工業的に極めて有利な方法である。
According to the method of the present invention, aryl halide and cyanacetate are reacted using a very small amount of catalyst, and aryl-substituted cyanacetate can be obtained in high yield, so it is an extremely advantageous method industrially. .

こうして得たアリニル置換シアン酢酸エステルは2例え
ば医薬、農薬、動物薬、各種生理活性物質、染料9機能
性ポリマー、液晶、有機導電材料(電解コンデンサー、
蓄電池、太陽電池、有機半導体などのエレクトロニクス
関連材料)などの中間体として利用される。     
       。
The thus obtained allinyl-substituted cyanacetic esters can be used, for example, in pharmaceuticals, agricultural chemicals, veterinary drugs, various physiologically active substances, dyes, functional polymers, liquid crystals, organic conductive materials (electrolytic capacitors,
It is used as an intermediate for storage batteries, solar cells, electronics-related materials such as organic semiconductors), etc.
.

次に実施例を挙げて本発明を説明する。Next, the present invention will be explained with reference to Examples.

実施例1 還流冷却器、攪拌機1滴下漏斗及び温度計を備えた三ツ
−フラスコに、窒素気流中で、カリウムt−ブトキサイ
ド2.47 ? (22mmol )及びエチレングリ
コールジメチルエーテ)V40ml  を入れ、これに
シアン酢酸エチlv1.451 (13mmol )の
エチレングリコールジメチルエーテルiI液(if)r
rLl)  ヲ徐々に加えた。その後ヨードベンセン2
.04 ? (lQmmol )及ヒ触媒としてンクロ
オクタジエンパラジウムジクロライド57■(0,2m
mol )ト)リフェニ/レホスフィン105η(04
mmol )を加え、攪拌しながら、70℃で8時間反
応させた。溶媒を留去した後、蒸留を行ない沸点154
〜156℃/11 mmHz  のフェニルシアン酢酸
エチルを1.459得た。収率は76.5%であった。
Example 1 In a three-piece flask equipped with a reflux condenser, a stirrer, an addition funnel, and a thermometer, 2.47 ml of potassium t-butoxide was added in a nitrogen stream. (22 mmol) and ethylene glycol dimethyl ether) V40 ml, and ethylene glycol dimethyl ether II solution (if) r of ethyl cyanacetate lv1.451 (13 mmol)
rLl) was added gradually. Then iodobenzene 2
.. 04? (lQmmol) and Ncrooctadienepalladium dichloride 57cm (0.2mmol) as a catalyst
mol) Tripheni/Lephosphine 105η(04
mmol) was added thereto, and the mixture was reacted at 70° C. for 8 hours while stirring. After distilling off the solvent, distillation is performed to reduce the boiling point to 154
1.459 phenylcyanoethyl acetate was obtained at ~156°C/11 mmHz. The yield was 76.5%.

実施例2〜12 実施例1と同じ反応容器に、下記第1表の塩基性縮合剤
及び溶媒を入れ、シアン酢酸エチル1.45 F (1
3mmol )の溶液(10m7りを徐々に加えた。
Examples 2 to 12 Into the same reaction vessel as in Example 1, put the basic condensing agent and solvent shown in Table 1 below, and add 1.45 F (1
3 mmol) solution (10 mL) was gradually added.

次にヨードベンゼ:/ 2.04 S’ (lQmmo
l )と下記第1表の触媒を添加し9反応させた。その
後は実施例1と同様の反応及び操作を行ない、沸点15
4〜156℃/llmmHg のフェニルシアン酢酸エ
チル(反応生成物)を得た。
Next, iodobenze: / 2.04 S' (lQmmo
1) and the catalyst shown in Table 1 below were added and reacted for 9 times. Thereafter, the same reactions and operations as in Example 1 were carried out, and the boiling point was 15.
Ethyl phenylcyanoacetate (reaction product) having a temperature of 4 to 156°C/llmmHg was obtained.

結果を第1表に示した。The results are shown in Table 1.

(注)第1表中の記号は次のことを表わす。(Note) The symbols in Table 1 represent the following.

Ph:フェニル基、 Et :エチル基+ Bu ニブ
チル基。
Ph: phenyl group, Et: ethyl group + Bu nibutyl group.

M、e :メチル基、 Am ニアミル基、 CHD 
ニジクロヘキサジエン、 COD ニジクロオクタジエ
ン、NBD:ノルボルナジエン。
M, e: methyl group, Am nearyl group, CHD
Nidichlorohexadiene, COD Nidichlorooctadiene, NBD: norbornadiene.

実施例13〜28 実施例1と同様の反応容器に、上記第2−1表及び第2
−2表の塩基性縮合剤22mmo1及び溶媒40rnl
を入れ、これにシアン酸エヌテ)v 13 m mol
の溶液(10d)を徐々に加えた。その後アリールハラ
イド10mmo!及び触媒としてシクロオクタジエンパ
ラシラムシクロライド57■(0,2mmol ) ト
トリフェニルホヌフィン105 my (0,4mmo
l )を添加し反応させた。その後は実施例1と同様の
反応及びm 作’t 行ない、アリール置換シアン酢酸
エヌテル(反応生成物)を得た。
Examples 13 to 28 The above Table 2-1 and Table 2 were placed in the same reaction container as in Example 1.
-22 mmol of basic condensing agent and 40 rnl of solvent from Table 2
and add cyanic acid NTE) v 13 m mol
solution (10d) was added gradually. Then aryl halide 10mmo! and cyclooctadieneparasyram cyclolide 57 my (0.2 mmol) totriphenylhonuphine 105 my (0.4 mmol) as a catalyst.
l) was added and reacted. Thereafter, the same reactions and operations as in Example 1 were carried out to obtain aryl-substituted cyanoacetate (reaction product).

なお1分子中に反応性ハロゲン原子(例えば臭素原子、
ヨウ素原子)を二個有するアリールハライド10mmo
lを用いる場合は、上記において塩基性縮合剤50mm
ol  、 シアン酢酸x ヌテ/L/ 40 rr!
mol 。
Note that reactive halogen atoms (e.g. bromine atoms,
Aryl halide with two iodine atoms) 10 mmo
When using l, in the above basic condensing agent 50mm
ol, cyanacetic acid x Nute/L/40 rr!
mol.

溶媒50−を使用して行なった。It was carried out using solvent 50-.

以上の結果を第2−1表及び第2−2表に示した。The above results are shown in Table 2-1 and Table 2-2.

(注)第2−1表及び第2−2表中の記号は次のことを
表わす。
(Note) The symbols in Tables 2-1 and 2-2 represent the following.

Me:メチル基、Et:エチル基+ ’Pr ’  イ
ソプロピル基+ Bu ニブチル基。
Me: methyl group, Et: ethyl group + 'Pr' isopropyl group + Bu nibbutyl group.

Claims (1)

【特許請求の範囲】 触媒、塩基性縮合剤及び溶媒の存在下に、 一般式 Ar−Xm又は▲数式、化学式、表等があります▼ (式中Arはアリール基又はアリーレン基を、Xはハロ
ゲン原子を、Yは−O−、−S−又はアルキレン基を、
mは1又は2の整数を、nは0又は1の整数をそれぞれ
示す)で表わされるアリールハライドに 一般式 CNCH_2COOR^1 (式中R^1はアルキル基、アラルキル基又はアリール
基を示す)で表わされるシアン酢酸エステルを反応させ
るに当り、触媒として (a)一般式 Q_aPd(II)X^*_b 〔式中Qはニトリル類、イソニトリル類、π−アリル、
1,5−ジエン類、1,3−ジエン類、ベンゾキノン又
はオレフィン類を示し、但し、これらの化合物はPd(
II)錯体を形成するものとし、X^*はハロゲン原子を
、a及びbは1又は2の整数をそれぞれ示す〕で表わさ
れる二価のパラジウム錯体と (b)一般式 ▲数式、化学式、表等があります▼ (式中Zはリン原子、ヒ素原子又はアンチモン原子を、
R^3、R^4又はR^5はアルキル基、アルケニル基
、アラルキル基、アリール基、シクロアルキル基、アル
コキシ基又はアリールオキシ基から独立して選ばれた基
を示し、R^3、R^4又はR^5が他の分子のR^3
、R^4又はR^5と互に結合し、少なくとも1個のア
ルキレン基又はアルキレンエーテル基を形成していても
よい)で表わされる配位子化合物を用いて該反応を行な
うことを特徴とする、 一般式 ▲数式、化学式、表等があります▼ 又は ▲数式、化学式、表等があります▼ (式中Ar、R^1、Y、m、及びnは上記と同じ意義
を有する)で表わされるアリール置換シアン酢酸エステ
ルの製造方法。
[Claims] In the presence of a catalyst, a basic condensing agent, and a solvent, there is a general formula Ar-Xm or ▲mathematical formula, chemical formula, table, etc.▼ (where Ar is an aryl group or an arylene group, and atom, Y is -O-, -S- or alkylene group,
m is an integer of 1 or 2, and n is an integer of 0 or 1, respectively) with the general formula CNCH_2COOR^1 (wherein R^1 is an alkyl group, an aralkyl group, or an aryl group). In reacting the cyanacetic acid ester represented by the formula (a) as a catalyst, the general formula Q_aPd(II)X^*_b [wherein Q is nitriles, isonitriles, π-allyl,
Indicates 1,5-dienes, 1,3-dienes, benzoquinone or olefins, provided that these compounds are Pd(
II) A divalent palladium complex represented by (b) General formula ▲ Numerical formula, chemical formula, table etc.▼ (In the formula, Z is a phosphorus atom, arsenic atom or antimony atom,
R^3, R^4 or R^5 represents a group independently selected from an alkyl group, an alkenyl group, an aralkyl group, an aryl group, a cycloalkyl group, an alkoxy group or an aryloxy group, and R^3, R ^4 or R^5 is R^3 of another molecule
, R^4 or R^5, and may form at least one alkylene group or alkylene ether group). Represented by the general formula ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ or ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ (In the formula, Ar, R^1, Y, m, and n have the same meanings as above) A method for producing an aryl-substituted cyanacetic ester.
JP59226071A 1984-10-27 1984-10-27 Preparation of aryl-substituted cyanoacetic acid ester Pending JPS61103861A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP59226071A JPS61103861A (en) 1984-10-27 1984-10-27 Preparation of aryl-substituted cyanoacetic acid ester

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59226071A JPS61103861A (en) 1984-10-27 1984-10-27 Preparation of aryl-substituted cyanoacetic acid ester

Publications (1)

Publication Number Publication Date
JPS61103861A true JPS61103861A (en) 1986-05-22

Family

ID=16839352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59226071A Pending JPS61103861A (en) 1984-10-27 1984-10-27 Preparation of aryl-substituted cyanoacetic acid ester

Country Status (1)

Country Link
JP (1) JPS61103861A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525371A (en) * 2010-04-22 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド Method for producing cycloalkylcarboxamide-indole compound
US9732080B2 (en) 2006-11-03 2017-08-15 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US9758510B2 (en) 2006-04-07 2017-09-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9974781B2 (en) 2006-04-07 2018-05-22 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10058546B2 (en) 2012-07-16 2018-08-28 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof
US10081621B2 (en) 2010-03-25 2018-09-25 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10975061B2 (en) 2006-04-07 2021-04-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9758510B2 (en) 2006-04-07 2017-09-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US11639347B2 (en) 2006-04-07 2023-05-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10239867B2 (en) 2006-04-07 2019-03-26 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9974781B2 (en) 2006-04-07 2018-05-22 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US10987348B2 (en) 2006-04-07 2021-04-27 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US9732080B2 (en) 2006-11-03 2017-08-15 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US10906891B2 (en) 2010-03-25 2021-02-02 Vertex Pharmaceuticals Incoporated Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US11578062B2 (en) 2010-03-25 2023-02-14 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US10081621B2 (en) 2010-03-25 2018-09-25 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
JP2017071650A (en) * 2010-04-22 2017-04-13 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Processes of producing cycloalkylcarboxamido-indole compounds
US10071979B2 (en) 2010-04-22 2018-09-11 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
JP2013525371A (en) * 2010-04-22 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド Method for producing cycloalkylcarboxamide-indole compound
US10058546B2 (en) 2012-07-16 2018-08-28 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof
US11951212B2 (en) 2014-04-15 2024-04-09 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US10980746B2 (en) 2014-04-15 2021-04-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

Similar Documents

Publication Publication Date Title
CA2502342C (en) Ruthenium complexes as (pre)catalysts for metathesis reactions
Venier et al. Di-tert-butylcyclopentadiene and tri-tert-butylcyclopentadiene
Achar et al. Organoplatinum (IV) polymers and model complexes by oxidative addition of bromoacetate esters
KR100581624B1 (en) Method of Manufacturing Phosphine Compound
US5892075A (en) Process for synthesizing metallocene compounds
JPS61103861A (en) Preparation of aryl-substituted cyanoacetic acid ester
JP4550413B2 (en) Novel transition metal complexes and their use in transition metal-catalyzed reactions
US5380861A (en) Process for preparing pyridine 2-carboxamides
Matsuo et al. Synthesis and structural characterization of 2, 5-bis (N-aryliminomethyl) pyrrolyl complexes of aluminum
Guo et al. Potassium complexes containing bidentate pyrrole ligands: synthesis, structures, and catalytic activity for the cyclotrimerization of isocyanates
CN108864327A (en) 5,6- dimethyl acenaphthene(Alpha-diimine)Nickel alkene catalyst and its preparation and application
US6127583A (en) Process for preparing acetylene derivative from a ketone compound
US4668816A (en) High yield carbonylation of halo-hydrocarbons
Margaretha et al. Synthesis of imines of. alpha.,. beta.-acetylenic ketones
US3839387A (en) Process for preparing n-trimethyl-silylacetamide
JPS60204753A (en) Preparation of aryl-substituted malonitrile
US5034534A (en) Process for producing saccharin, saccharin analogues or their salts
JPS6117553A (en) Praparation of aryl-substituted cyanoacetic ester
JPH0568460B2 (en)
US4761499A (en) Carbonylation of vinyl dihalides
Amsallem et al. New types of stable aldehydes: Formylphosphane and formylphosphane oxide
US4045447A (en) Process for preparing 2-vinyl oxazolines
RU2323921C2 (en) Preparation of substituted indenes
JPH06234668A (en) Production of 9,9-dialkylfulorene
JPH0543485A (en) Synthesis of substituted allylbenzene